TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33857411
Drug: Lobaplatin-based induction
Normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobaplatin-based induction chemotherapy (lobaplatin 30 mg/m2 on days 1 and 22, fluorouracil 800 mg/m2 on days 1-5 and 22-26 for two cycles) followed by concurrent lobaplatin-based chemoradiotherapy.
Study: 33857411
Drug: Cisplatin-based induction
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based induction chemotherapy (cisplatin 100 mg/m2 on days 1 and 22, fluorouracil 800 mg/m2 on days 1-5 and 22-26 for two cycles) followed by concurrent cisplatin-based chemoradiotherapy.
Study: 33857411
Drug: Lobaplatin-based induction
Normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobaplatin-based induction chemotherapy (lobaplatin 30 mg/m2) in per-protocol population.
Study: 33857411
Drug: Cisplatin-based induction
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based induction chemotherapy (cisplatin 100 mg/m2) in per-protocol population.
Study: 36964977
Drug: Insulin dose
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dose
Study: 38484209
Drug: Targeted agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted agents
Study: 36385038
Drug: PCIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIA with low basal infusion
Study: 36385038
Drug: PCIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIA with no basal infusion
Study: 33759742
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy for social anxiety disorder in adolescents (CT‐SAD‐A)
Study: 34610572
Drug: ZIKV-Ig (50.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZIKV-Ig (50.0 mL intravenous dose)
Study: 34370331
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) - no treatment
Study: 36168148
Drug: Riluzole oral
Normalized name: riluzole Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole oral film (ROF) 50 mg
Study: 36168148
Drug: Riluzole tablets
Normalized name: Riluzole Tablets
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole tablets 50 mg
Study: 36168148
Drug: Riluzole oral
Normalized name: riluzole Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole oral film (ROF) 50 mg with food
Study: 34688917
Drug: Pioglitazone (PPAR-γ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (PPAR-γ agonist) adjunctive to cognitive-behavioral therapy (CBT)
Study: 34628066
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) therapy using a 670-nm light-emitting eye patch, applied for 90 seconds twice daily for 4 months.
Study: 34628066
Drug: Placebo using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo using an identical device emitting broad-spectrum white light at low power, applied for 90 seconds twice daily for 4 months.
Study: 33095939
Drug: Pomegranate fruit
Normalized name: Pomegranate Fruit
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate fruit extract (PFE) 1000 mg once daily for twelve months
Study: 35951068
Drug: Thymosin α1
Normalized name: chymosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin α1 plus blood purification (BP) therapy
Study: 35951068
Drug: Blood purification
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood purification (BP) treatment only
Study: 32871870
Drug: PPI (Omeprazole;
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI (Omeprazole; 40 mg twice daily)
Study: 32303499
Drug: Monthly ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly ranibizumab 0.3 mg every 4 weeks
Study: 35869988
Drug: Nicotine pouches
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine pouches (NPs) with 1.5 mg nicotine
Study: 35869988
Drug: Nicotine pouches
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine pouches (NPs) with 2 mg nicotine
Study: 35869988
Drug: Nicotine pouches
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine pouches (NPs) with 3.5 mg nicotine
Study: 35869988
Drug: Nicotine pouches
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine pouches (NPs) with 8 mg nicotine
Study: 616873944
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management with interventional therapy
Study: 33010241
Drug: Efavirenz 400
Normalized name: efavirenz 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 400 mg
Study: 33130059
Drug: Vancomycin solution
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin solution (5 mg/mL) soaking for 30 minutes
Study: 35358738
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin
Study: 35732845
Drug: 4 oz
Normalized name: Oval Amber 4 oz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 oz prunes daily plus docusate sodium 100 g twice daily
Study: 32807539
Drug: Teaching intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teaching intervention combining lay language, simplified handouts, provision of an unmarked dosing syringe, and teach-back to confirm correct dosing.
Study: 32669375
Drug: Ganetespib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib (200 mg/m2, days 1 and 15) with pemetrexed (500 mg/m2, day 1) and cisplatin (75 mg/m2, day 1) or carboplatin (AUC 5, day 1)
Study: 32669375
Drug: Ganetespib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib at MTD (200 mg/m2)
Study: 34971646
Drug: Peanut allergen
Normalized name: PEANUT ALLERGEN-DNFP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut allergen powder-dnfp (PTAH) during 300 mg maintenance
Study: 32654042
Drug: No post-surgical
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No post-surgical treatment (Group B)
Study: 32214138
Drug: Rosuvastatin (less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (less favorable treatment response)
Study: 39133200
Drug: secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 300 mg
Study: 33509804
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg metformin
Study: 33509804
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg metformin
Study: 33509804
Drug: Metformin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (both dosages)
Study: 32320773
Drug: Curettage and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curettage and imiquimod cream
Study: 33280441
Drug: Astragalus membranaceus
Normalized name: Astragalus membranaceus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus membranaceus polysaccharide (APS) treatment
Study: 32903261
Drug: Oral stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral stimulation program
Study: 32700919
Drug: Indigenously adapted
Normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigenously adapted cognitive‐behavioral therapy for excessive smartphone use (IACBT‐ESU)
Study: 36251032
Drug: L-asparaginase Medac
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase Medac (historical control)
Study: 32213316
Drug: Colistin (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin (9 million units loading dose, followed by 4.5 MU twice daily maintenance dose)
Study: 34582552
Drug: 1 cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cup of coffee + 2 CBPCC twice daily (PC)
Study: 33484509
Drug: Physiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy with manual therapy
Study: 34346946
Drug: Topical fluoride
Normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoride varnish application (Duraphat; Colgate)
Study: 32858717
Drug: Massage (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage (daily 30-minute massage for 7 days)
Study: 32858717
Drug: Control (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (daily 30-minute restriction of nonessential caregiving for 7 days)
Study: 34936740
Drug: Multicomponent diagnostic
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent diagnostic strategy (on-site molecular testing, guided restructuring of clinic workflows, monthly feedback of quality metrics)
Study: 32120028
Drug: Liothyronine (L-T3)
Normalized name: L-T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liothyronine (L-T3) 75 mcg total daily dose (TDD)
Study: 38204957
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups combined
Study: 34959798
Drug: Glucose beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose beverage (125 mL semi-skimmed milk and 50 g glucose)
Study: 34959798
Drug: Intermittent sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent sucrose beverage (125 mL semi-skimmed milk and 50 g sucrose)
Study: 34959798
Drug: Sucrose beverage
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose beverage (125 mL semi-skimmed milk and 50 g sucrose)
Study: 34959798
Drug: Isomaltulose beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomaltulose beverage (125 mL semi-skimmed milk and 50 g isomaltulose)
Study: 37752466
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment
Study: 36304565
Drug: CYP2D6 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2D6 genotype treatment (G)
Study: 32662840
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy at a power of 2 J/cm2 with a total of 4-6 J energy over each implant
Study: 34937512
Drug: Recombinant follitropin/lutropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant follitropin/lutropin alfa within the protocol of applying gonadotropin-releasing hormone antagonists
Study: 35007129
Drug: LSVT‐1701, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSVT‐1701, 6 mg/kg single dose
Study: 35007129
Drug: LSVT‐1701, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSVT‐1701, 1.5 mg/kg twice daily for 4 days
Study: 35007129
Drug: LSVT‐1701, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSVT‐1701, 3 mg/kg twice daily for 4 days
Study: 35007129
Drug: LSVT‐1701, 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSVT‐1701, 4.5 mg/kg twice daily for 4 days
Study: 33409684
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of meropenem (3 g daily) for 48 hours
Study: 33409684
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose of meropenem based on Cockcroft‐Gault equation
Study: 33409684
Drug: Standard and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard and adjusted doses of meropenem
Study: 32114502
Drug: Acalabrutinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib monotherapy (100 mg twice daily)
Study: 32114502
Drug: Acalabrutinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib combined with pembrolizumab (200 mg on day 1 of each 3-week cycle)
Study: 33681744
Drug: Intramuscular olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular olanzapine
Study: 32385647
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml sodium chloride and 20 mg furosemide
Study: 32385647
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml sodium chloride and 40 mg furosemide
Study: 32385647
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml sodium chloride
Study: 32648395
Drug: herb-separated moxibustion
Normalized name: serrated swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: herb-separated moxibustion combined with budesonide nasal spray (rhinocort), 64 μg each spray, twice daily for 4 weeks
Study: 32648395
Drug: budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide nasal spray (rhinocort), 64 μg each spray, twice daily for 4 weeks
Study: 35691371
Drug: 4-month relational
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month relational agent coupled with AliveCor Kardia for heart rate and rhythm monitoring
Study: 33983076
Drug: Manual preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual preparation of saline syringes
Study: 35303929
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with propofol and intravenous lidocaine
Study: 35303929
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with sevoflurane and intravenous lidocaine
Study: 33308131
Drug: Biological therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological therapies
Study: 32224233
Drug: Oral antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidiabetic drugs (glyburide, metformin, or pioglitazone)
Study: 32224233
Drug: ETA-receptor blockade
Normalized name: Blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETA-receptor blockade
Study: 35974101
Drug: Treatment-related mortality
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related mortality
Study: 35449028
Drug: High-dose quadrivalent
Normalized name: Fluzone High-Dose Quadrivalent PF 2020-2021
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose quadrivalent influenza vaccine
Study: 35115339
Drug: Salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 200 µg
Study: 33624798
Drug: VVZ-149 Injections
Normalized name: Vvz-149 free base
DrugBank: Opiranserin (DB16271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVZ-149 Injections (10-hour intravenous infusion)
Study: 33247955
Drug: berotralstat 150
Normalized name: berotralstat 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: berotralstat 150 mg
Study: 33247955
Drug: berotralstat 110
Normalized name: berotralstat 110 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: berotralstat 110 mg
Study: 32588153
Drug: Daikenchuto (DKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (DKT) 15 g per day during the perioperative period
Study: 33934476
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement and topical solution containing nanosilicon
Study: 35981135
Drug: BROAD light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: BROAD light therapy (very brightly illuminated room for at least 6 hours per day for 4 weeks)
Study: 34304969
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care and exercise (3-weekly 40 min sessions of unsupervised, moderate-intensity home rowing program over 3 months)
Study: 32147878
Drug: Anatomical occlusal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatomical occlusal reduction with round shoulder preparation (Group OS)
Study: 32147878
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation of tooth (Control group)
Study: 32147878
Drug: Anatomical occlusal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anatomical occlusal reduction with round shoulder preparation and central groove (Group OSG)
Study: 36414518
Drug: local neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: local neck treatment (NT) + JPS/oculomotor exercises (JPS/OC)
Study: 36414518
Drug: local neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: local neck treatment (NT) + balance exercises
Study: 36414518
Drug: all treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all treatments (NT + JPS/OC + balance exercises)
Study: 36414518
Drug: local neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: local neck treatment (NT)
Study: 33798455
Drug: Pirfenidone (267
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (267 mg three times per day in week 1, 534 mg three times per day in week 2, and 801 mg three times per day thereafter)
Study: 35314480
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Tolvaptan + Hydrochlorothiazide)
Study: 32541171
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 ointment applied twice a day for 8 weeks
Study: 32541171
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied twice a day for 8 weeks
Study: 36082248
Drug: Maraviroc 150
Normalized name: maraviroc 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 150 or 600 mg/day
Study: 32513299
Drug: Anluohuaxian Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anluohuaxian Pill
Study: 32513299
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (basic therapeutic drugs for COVID-19)
Study: 34751506
Drug: Routine daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine daily activities (Control group)
Study: 32597619
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate supplementation (0.3 g/kg per day for 7 days)
Study: 34369695
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment with filiform needles inserted perpendicularly, 3 mm in depth, with electric stimulation (2 Hz, 30 min, 3 times a week for 14 treatments)
Study: 34369695
Drug: Placebo needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo needling method (needle not inserted through skin) with electric stimulation (2 Hz, 30 min, 3 times a week for 14 treatments)
Study: 32699168
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg once per day
Study: 32699168
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg once per day with CPAP
Study: 34034929
Drug: CNS-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS-directed therapy
Study: 37061656
Drug: DMF 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMF 240 mg twice daily
Study: 34161776
Drug: REGEN-COV (two-antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGEN-COV (two-antibody combination)
Study: 34161776
Drug: Single monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single monoclonal antibody treatments
Study: 34161776
Drug: Dual or
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual or triple antibody combinations (in vitro studies)
Study: 34340242
Drug: Text-based reminders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text-based reminders delivered one day after notification of vaccine eligibility
Study: 34340242
Drug: Text-based reminders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text-based reminders delivered eight days after notification of vaccine eligibility
Study: 34340242
Drug: First reminder
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First reminder designed to induce feelings of ownership over the vaccine dose
Study: 34340242
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of first reminder with a video-based information intervention
Study: 35757330
Drug: Shenqisuxin granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqisuxin granule (SQSX) plus conventional treatment
Study: 33188136
Drug: JAK inhibitors
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAK inhibitors (JAKi)
Study: 34269398
Drug: Specific vasoactive
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific vasoactive therapy
Study: 34269398
Drug: Underlying heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Underlying heart and lung disease treatment
Study: 35719836
Drug: Lycii Fructus
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lycii Fructus extract (LFE) 900 mg/day
Study: 32899031
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue plasminogen activator thrombolytic therapy
Study: 33354769
Drug: Daily smartphone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily smartphone-based monitoring including a feedback loop
Study: 35332521
Drug: Ultrasound-guided proximal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided proximal suprascapular nerve block with 5 ml ropivacaine 7.5 mg/ml
Study: 35332521
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml isotonic NaCl)
Study: 33106167
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care and 200 ml convalescent plasma (CP)
Study: 33106167
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care and 400 ml convalescent plasma (CP)
Study: 33106167
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care and 200 ml CP